Open AccessMETHODOLOGICAL ASPECTS OF THE PHASE II STUDY AFF006 EVALUATING AMYLOID-BETA -TARGETING VACCINE AFFITOPE® AD02 IN EARLY ALZHEIMER’S DISEASE – PROSPECTIVE USE OF NOVEL COMPOSITE SCALES
Author(s) -
Suzanne Hendrix,
Noel Ellison,
Stephanie H. Stanworth,
L. Tierney,
Frank Mattner,
Walter Schmidt,
Bruno Dubois,
Achim Schneeberger
Publication year - 2015
Publication title -
the journal of prevention of alzheimer's disease/jpad
Language(s) - English
Resource type - Journals
eISSN - 2426-0266
pISSN - 2274-5807
DOI - 10.14283/jpad.2015.67
Subject(s) - medicine , clinical trial , cognition , neuropsychology , placebo , psychology , psychiatry , pathology , alternative medicine
Optimized scales and composite outcomes have been proposed as a way to more accurately measure Alzheimer's disease related decline. AFFITOPE® AD02, is an amyloid-beta (Aβ)-targeting vaccine to elicit anti-Aβ antibodies. IMM-AD04, commonly known as Alum, originally designated as a control agent, appeared to have disease-modifying activity in a multicenter, parallel group phase II study in early AD patients.